Alumis shares slide about 56% after lupus trial misses primary and secondary endpoints
AI Market Summary
Alumis reported its Phase 2b LUMUS trial in moderate-to-severe SLE missed primary and secondary endpoints in the overall population, triggering an intraday stock collapse of roughly 56% and erasing about $1.5B in market value. While an IFNGS-high subgroup showed stronger efficacy, underrepresentation limits interpretability and raises development-path uncertainty. The outcome reinforces idiosyncratic biotech trial risk and can weigh on risk appetite across high-beta growth segments.
Impact level
● Medium
Affected assets
NCCOGOLD2USD/USDT-1.98%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Alumis said its Phase 2b LUMUS study of envudeucitinib in moderateto-severe systemic lupus erythematosus failed to meet both primary and secondary endpoints in the overall patient population. The trial enrolled 408 patients, and the primary endpoint at Week 48 did not reach statistical significance, despite stronger responses in a prespecified IFNGShigh subgroup. Following the update, Alumis shares fell about 56%, wiping out roughly $1.5B in market value.
